

Resource Summary Report

Generated by SPARC SAWG on Aug 11, 2026

TotalSeq(TM)-C0125 anti-human CD44

RRID:AB_2800900

Type: Antibody

Proper Citation

BioLegend Cat# 338827, RRID:AB_2800900

Antibody Information

URL: http://antibodyregistry.org/AB_2800900

Proper Citation: BioLegend Cat# 338827, RRID:AB_2800900

Target Antigen: CD44

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: PG

Antibody Name: TotalSeq(TM)-C0125 anti-human CD44

Description: This monoclonal targets CD44

Target Organism: human

Clone ID: Clone BJ18

Antibody ID: AB_2800900

Vendor: BioLegend

Catalog Number: 338827

Record Creation Time: 20250819T235301+0000

Record Last Update: 20250820T064306+0000

Ratings and Alerts

No rating or validation information has been found for TotalSeq(TM)-C0125 anti-human CD44.

No alerts have been found for TotalSeq(TM)-C0125 anti-human CD44.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Buus TB, et al. (2025) Divergent Evolution of Malignant Subclones Maintains a Balance between Induced Aggressiveness and Intrinsic Drug Resistance in T-cell Cancer. *Cancer discovery*, 15(10), 2036.

Marglous S, et al. (2025) Single-cell glycome and transcriptome profiling enabled by a library of anti-glycan antibodies. *Cell chemical biology*, 32(12), 1554.

Poch T, et al. (2024) Intergenic risk variant rs56258221 skews the fate of naive CD4+ T cells via miR4464-BACH2 interplay in primary sclerosing cholangitis. *Cell reports. Medicine*, 5(7), 101620.

Yang C, et al. (2024) Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy. *Cancer cell*, 42(12), 2064.

Ivanova EN, et al. (2023) mRNA COVID-19 vaccine elicits potent adaptive immune response without the acute inflammation of SARS-CoV-2 infection. *iScience*, 26(12), 108572.

Bachireddy P, et al. (2021) Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy. *Cell reports*, 37(6), 109992.